Honeydew founder says it is growing 3x year over year
In an October 24th Business Insider profile, David Futoran described Honeydew's growth and his decision to start low-dose isotretinoin. The article does not date that decision or say whether he was still taking it when the profile was published.
By RuntimeWire Staff · Published
Primary source: Business Insider
Why it matters
Honeydew is building around access to an existing prescription, not a new acne drug. Futoran's reported experience helps explain the appeal, while unresolved evidence on lower-dose regimens and isotretinoin's serious risks put the burden on clinical oversight, not convenience alone.
Honeydew co-founder David Futoran told Business Insider the company is growing 3x year over year, as interest in lower-dose isotretinoin rises. The profile, published October 24th, also recounts Futoran's decision to try the regimen. It does not say when he began taking it or whether he was still taking it on October 24th, so his account cannot establish a current treatment status.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.